These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3704943)

  • 1. [Therapy of hepatitis B virus carriers].
    Bereza NM; Petiĭ SI
    Ter Arkh; 1986; 58(2):65-7. PubMed ID: 3704943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis B carrier state.
    Murray BJ
    Am Fam Physician; 1986 Apr; 33(4):127-33. PubMed ID: 2938461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effects of HBsAg vaccine and levamisole in chronic hepatitis B and hepatitis B carrier children.
    Demirci F; Bayraktaroğlu Z; Karaoğlan M; Coşkun Y; Karaoğlan I; Okan V
    Turk J Gastroenterol; 2005 Dec; 16(4):188-93. PubMed ID: 16547845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection.
    Habersetzer F; Moenne-Loccoz R; Meyer N; Schvoerer E; Simo-Noumbissie P; Dritsas S; Baumert TF; Doffoël M
    Liver Int; 2015 Jan; 35(1):130-9. PubMed ID: 25145784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.
    Cornberg M; Protzer U; Dollinger MM; Petersen J; Wedemeyer H; Berg T; Jilg W; Erhardt A; Wirth S; Schirmacher P; Fleig WE; Manns MP
    Z Gastroenterol; 2007 Dec; 45(12):1281-328. PubMed ID: 18080231
    [No Abstract]   [Full Text] [Related]  

  • 6. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
    Lai CL; Ching CK; Tung AK; Li E; Young J; Hill A; Wong BC; Dent J; Wu PC
    Hepatology; 1997 Jan; 25(1):241-4. PubMed ID: 8985298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Active chronic hepatitis caused by the B virus (ACH-B). Recent pathogenetic acquisitions and elements of serological, clinical and histopathological diagnosis].
    Romeo F; Spina A; Cannaò G
    Recenti Prog Med; 1980 Dec; 69(6):577-643. PubMed ID: 6166032
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
    Renou C; Cadranel JF; Pariente A; Pénaranda G; Bourlière M; Halfon P; Igual JP; Harafa A; Muller P; Bertrand JJ; Laugier R
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1235-7. PubMed ID: 18989147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus genetic diversity.
    Echevarría JM; Avellón A
    J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis and therapy of HBsAg positive hepatitis.
    Weimar W; Schellekens H
    Biomedicine; 1979 Jul; 30(3):135-8. PubMed ID: 486686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of post-transfusion infection with the hepatitis delta virus. A multicenter study.
    Rosina F; Saracco G; Rizzetto M
    N Engl J Med; 1985 Jun; 312(23):1488-91. PubMed ID: 3990749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levamisole treatment of acute viral hepatitis and HBsAG-positive chronic active hepatitis.
    Pár A; Barna K; Bajtai G; Hollós I; Ambrus M; Kovács M; Jávor T
    Acta Med Acad Sci Hung; 1980; 37(3):269-81. PubMed ID: 7457030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus carriers; natural course, diagnostic approach and treatment.
    Ranjan P; Aggarwal R
    Trop Gastroenterol; 2005; 26(2):58-65. PubMed ID: 16225046
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011].
    Cornberg M; Protzer U; Dollinger MM; Petersen J; Wedemeyer H; Berg T; Jilg W; Erhardt A; Wirth S; Schirmacher P; Fleig WE; Manns MP
    Z Gastroenterol; 2007 Jun; 45(6):525-74. PubMed ID: 17554641
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunoradiometric analysis and the prevention of posttransfusion hepatitis B].
    Leĭbenzon AS; Malakhova TS; Anan'ev VA; Viazov SO; Shchegolev AS
    Vopr Virusol; 1988; 33(3):292-4. PubMed ID: 3176430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparent cure of hepatitis C virus carrier state after hepatitis B virus superinfection.
    Yoshinaga S; Fukushima S; Masaki N; Hayashi S
    Jpn J Infect Dis; 1999 Oct; 52(5):220. PubMed ID: 10680091
    [No Abstract]   [Full Text] [Related]  

  • 19. Occult hepatitis B virus infection.
    Allain JP
    Transfus Clin Biol; 2004 Feb; 11(1):18-25. PubMed ID: 14980545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
    Mo YQ; Liang AQ; Ma JD; Chen LF; Zheng DH; Schumacher HR; Dai L
    BMC Musculoskelet Disord; 2014 Dec; 15():449. PubMed ID: 25532827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.